Robert F. Spiera, MD

If your insurance is not listed, please call our office if you have questions regarding your insurance coverage. If you have out-of-network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.

Appointments

Affiliations

Fellow, American College of Rheumatology
Fellow, American College of Physicians
Member, American Medical Association
Chairman, Scleroderma Foundation Tri State Chapter Medical Advisory Board
Member, Vasculitis Foundation Scientific Advisory Board
Member of Medical Advisory Board, Scleroderma Foundation (National)
Member, Subcommittee Research, Scleroderma Foundation Tri-State

Certification

Rheumatology
Internal Medicine

Awards

Castle Connolly Top Doctors in New York Metro Area, 2021, 2022
New York Magazine Top Doctors, 2021, 2022
Emmanuel Rudd, M.D. and Martin Gardy, M.D. Best Rheumatology Fellow Teacher Award, 2006
Founders Award Recipient for Clinical Investigation – Scleroderma Foundation, 2005
The Globus Award (Outstanding article in Mount Sinai Journal of Medicine) – Mount Sinai School of Medicine, 1998

Education

MD, Yale University School of Medicine, New Haven, CT, 1989
Residency: Internal Medicine, NY Hospital, New York, NY, 1989-1992
Fellowship: Rheumatology, Hospital for Special Surgery, NY, 1992-1995

State Licensure

Languages

English, Spoken by Office Staff: Spanish, French

Selected Journal Articles

For all publications, please see the PubMed listing.

Selected Books/Chapters

• Spiera RF, Kagen LJ. Collagen vascular diseases: Polymyositis, dermatomyositis, and inclusion body myositis. In: Therapy of Systemic Rheumatic Disorders (eds, Furst D, van Riel P, Williams J), Marcell Decker, Inc,. New York, NY, 1998.
  
  
• Spiera RF. Systemic Sclerosis and related disorders. In: Manual of Rheumatology and outpatient orthopedic disorders. (eds, Paget S, Gibofsky A, Pellici P), Little Brown and Co., Boston, 2000.
  
  
• Spiera RF. Hyperlipoproteinemia and arthritis. In: Primer on the Rheumatic Diseases, 12th edition. (eds, Klippel J, Crawford L, Stone J, Weyand C), Atlanta: Arthritis Foundation, 2001.
  
  
• Spiera RF. Polymyalgia Rheumatica, Giant Cell Arteritis and Takayasu's Arteritis. In: Expert Guide to Rheumatology. (eds, Yee AMF, Paget SA), Am College of Physicians, Phil, PA, 2005.
  
  
• Spiera RF, Spiera, H. How Can I Be Sure It Is Really Sjögren's? The NewSjögren's Syndrome Handbook, 3rd edition. (ed Wallace DJ), Oxford University Press,Inc., New York, NY, 2005.
  
  
• Paget SP, Spiera RF. Polymyalgia Rheumatica and Temporal Arteritis . In: Cecil's Textbook of Medicine, 23d edition, (eds, Goldman L, Ausiello D), Saunders, an imprint of Elsevier Inc., 2007 (292), 2059-2062.
  
  
• Paget SP, Spiera RF. Polymyalgia Rheumatica In: Clinical Care in the Rheumatic Diseases, 3rd edition, (24), 153-157.
  
  
• Spiera RF, Paget SP, Polymyalgia Rheumatica and Temporal Arteritis . In: Cecil's Textbook of Medicine, 24th edition 2010
  
  
• Spiera RF, Spiera, H. "Why is Sjögren's so hard to diagnose?" The Sjögren's Syndrome Handbook, 4th edition. (ed Wallace DJ), Oxford University Press,Inc., New York, NY, 2010
  
  

Clinical Trials / Research Studies

• A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis
• A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (Ssc-ILD)
• A 52 Week, Randomized, Double Blind Double-Dummy, Parallel-Group, Multi-Center, Non-Inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults with Relapsing or Refractory Eosinophilic Granulomatosis
• Abatacept (CTLA4-lg) for the Treatment of Relapsing, Non Severe, Granulomatosis with Polyangiitis (Wegener’s) (ABROGATE)
• Gleevec in the Treatment of Systemic Sclerosis - EXTENSION STUDY
• Scleroderma Registry and Repository (Old IRB #26069)
• Randomized, Double-Blind, Placebo-Controlled Trial of IL1-Trap, Rilonacept in Systemic Sclerosis-A Phase I/II Biomarker Trial (Old IRB #14115)
• VCRC Genetic Repository One Time DNA Protocol - 2016
• The Natural History and Outcome of Scleroderma Patients at High Risk or with Early Pulmonary Hypertension: a Multicenter Study Performed by from the Scleroderma Clinical Trials Consortium (PHAROS)
• Prospective Registry of Early Systemic Sclerosis (PRESS)- Phenotypic, Serologic, and Biomarker/Genetic Characteristics of Early Diffuse Cutaneous Scleroderma
• A Double Blind, Randomized, Placebo-Controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients with “Systemic Sclerosis associated Interstitial Lung Disease” (SSc-ILD)
• The LOTUSS Trial: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone When Administered to Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
• An International, Open Label, Randomized Controlled Trial Comparing Rituximab with Azathioprine as Maintenance Therapy in Relapsing ANCA-Associated Vasculitis
• ASCI: A Randomized, Double-blind, Placebo-controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
• A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects with Giant Cell Arteritis
• Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission in Wegener’s Granulomatosis and Microscopic Polyangiitis
• Prospective, Observational Safety Study Of Patients With Granulomatosis With Polyangiitis (Wegener’s) Or Microscopic Polyangiitis Treated With Rituximab
• VCRC Genetic Repository One Time DNA Protocol - 2013
• Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients with Ischemic Digital Ulcers Associated with Systemic Sclerosis
• Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica
• Phase II/III, Multicenter, Randomized, Double-blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab vs. Placebo in Patients with Systemic Sclerosis
• Studies of Immune Deregulation in Patients with Rheumatoid Arthritis, Polymyalgia Rheumatica and Vasculitis
• Natural History and Outcome of Scleroderma Patients at High Risk or with Early Pulmonary Hypertension
• Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
• Abatacept in Large Vessel Vasculitis
• Nilotinib in the Treatment of Systemic Sclerosis
• DISTOL 1: Digital Ischemic Lesions in Scleroderma Treated with Oral Treprostinil Diethanolamine: a Randomized, Double-blind, Placebo-controlled, Multicenter Study
• Scleroderma Cyclophosphamide or Transplantation (SCOT) Study
• The Myositis Registry and Repository - 2011
• Rituximab Therapy For The Induction Of Remission And Tolerance In ANCA-Associated Vasculitis
• Gleevec in the Treatment of Systemic Sclerosis

Patient Registries

• Dr. Spiera is a principal investigator for these patient registries.